AX-2025-018613

GHRP-6 · 2 mg declared · ChinaPeptides Co., Ltd. (QYAOBIO) · lot QYB-2504-H5023

PASSIDENTITY CONSISTENT

Report ID: AX-2025-018613
Compound: GHRP-6
Compound class: Growth-hormone axis peptides
Supplier: QYB — ChinaPeptides Co., Ltd. (QYAOBIO)
Batch / lot: QYB-2504-H5023
Declared label claim: 2mg
Laboratory: PeptideMeter
Assay date: 31 May 2025
Submitted: 10 Jun 2025
Quarter: 2025-Q2
Submitter: charge_envelope
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	99.34	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.66	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — des-Lys (−128 Da)	0.29	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	872.4446	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	872.4416	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-3.4	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	6.32	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	7.03	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.72	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.04	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	8.04	min	7.92 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.99	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	60,736	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.84	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 60,736, and skew follows the reported asymmetry factor of 0.99. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.29 % impurity against a 99.34 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-6 — main peak	8.04	4,828,232	99.34	—
2	des-Lys (−128 Da)	7.83	14,095	0.29	-128.095
3	oxidised Trp (+16 Da)	7.72	12,637	0.26	+15.995
4	[D-Trp]-epimer	7.93	3,888	0.08	0.000
5	bis-oxidised Trp (+32 Da)	7.50	1,458	0.03	+31.990
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 872.4446 Da, computed from C46H56N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 872.4416 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	437.2296	437.2281	-0.0015	55.3
1+	873.4519	873.4489	-0.0030	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.40	99.34	divergence -0.05 pp vs batch median
Total impurities (% area)	0.60	0.66
Largest single impurity (% area)	0.35	0.29
Water (%)	4.7	6.32
Counter-ion (%)	6.6	7.03
Peptide content (%w/w)	88.1	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 33 d) → laboratory (hand-carried, 2 d) → assay.
Assay date: 31 May 2025
Submitted to the index: 10 Jun 2025
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

c18_2p610 Jun 2025

Column chemistry flatters or punishes a figure like this. A core-shell column at this gradient resolves the close-eluting family that a fully porous 5 µm bed merges, so 99.34 % here is a harder number than the same figure from a coarser column.

gradient_2510 Jun 2025

The gradient is on the record, which is the first thing that should be true of any purity figure and often is not. 28 min at PeptideMeter puts this comparison on a documented footing.

buyer_sourced10 Jun 2025

Provenance and purity together are what make a figure like this usable. An independently purchased vial at 99.34 % is worth several supplier-selected ones.

Section 7

Related records

Same batch — lot QYB-2504-H5023 n=13

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-018610	QYB-2504-H5023	Janoshik	2025-Q2	99.40	6.40	—	Buyer-sourced	0	PASS
AX-2025-018611	QYB-2504-H5023	PeptideMeter	2025-Q2	99.51	6.57	99.6	Buyer-sourced	0	PASS
AX-2025-018612	QYB-2504-H5023	Janoshik	2025-Q2	99.57	6.23	—	Buyer-sourced	0	PASS
AX-2025-018614	QYB-2504-H5023	VendorInvestigate	2025-Q2	98.95	6.22	95.6	Buyer-sourced	0	FAIL
AX-2025-018615	QYB-2504-H5023	Janoshik	2025-Q2	99.45	6.23	89.1	Laboratory-retained	1	MARGINAL
AX-2025-018616	QYB-2504-H5023	PeptideMeter	2025-Q2	99.50	6.05	—	Buyer-sourced	0	PASS
AX-2025-018617	QYB-2504-H5023	PeptideMeter	2025-Q2	99.28	6.02	—	Buyer-sourced	0	PASS
AX-2025-018618	QYB-2504-H5023	Janoshik	2025-Q2	99.04	6.53	—	Buyer-sourced	0	PASS
AX-2025-018619	QYB-2504-H5023	Medutest	2025-Q2	99.89	6.65	94.3	Laboratory-retained	0	PASS
AX-2025-018620	QYB-2504-H5023	Janoshik	2025-Q2	99.49	6.08	—	Buyer-sourced	0	PASS
AX-2025-018621	QYB-2504-H5023	PeptideMeter	2025-Q2	99.25	6.81	—	Buyer-sourced	0	PASS
AX-2025-018622	QYB-2504-H5023	Janoshik	2025-Q2	99.65	6.68	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-6 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042012	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-042528	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	98.69	1.87	95.8	Buyer-sourced	0	FAIL
AX-2026-042015	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS
AX-2026-042526	HJ	HJ-2603-R5329	Medutest	2026-Q3	99.37	3.06	—	Laboratory-retained	0	PASS
AX-2026-042527	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	99.21	2.77	93.2	Buyer-sourced	0	PASS
AX-2026-042525	HJ	HJ-2603-R5329	Janoshik	2026-Q3	99.52	3.24	92.0	Buyer-sourced	0	PASS
AX-2026-042013	AMB	AMB-2603-S5667	Kestrel	2026-Q3	99.93	5.75	—	Buyer-sourced	0	PASS
AX-2026-042017	AMB	AMB-2603-S5667	Medutest	2026-Q3	99.76	6.42	97.4	Buyer-sourced	0	PASS

Other recent QYB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041471	PT-141 (Bremelanotide)	QYB-2607-L4875	Janoshik	2026-Q3	99.72	3.75	101.7	Buyer-sourced	0	PASS
AX-2026-041377	Ipamorelin	QYB-2605-H3558	Nordanalyt	2026-Q3	99.93	4.35	—	Buyer-sourced	0	PASS
AX-2026-041427	Retatrutide	QYB-2604-B4920	PeptideMeter	2026-Q3	97.93	2.45	101.7	Buyer-sourced	0	PASS
AX-2026-041428	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.35	3.20	—	Laboratory-retained	0	PASS
AX-2026-041473	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.58	3.74	94.4	Buyer-sourced	0	PASS
AX-2026-041472	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.93	3.94	—	Buyer-sourced	0	PASS
AX-2026-041429	Retatrutide	QYB-2604-B4920	Medutest	2026-Q3	98.53	2.69	99.8	Buyer-sourced	1	MARGINAL
AX-2026-041431	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.63	2.32	94.2	Buyer-sourced	0	PASS